

# Unacceptable co-formulants in PPPs

Jeremy Pinte, E4

**Advisory Group,** 29/04/2016





#### Content


- Context
- Setting Annex III
  - Criteria
  - Procedure
- Next steps
- Q&A





## Context (1/2)

PPP: formulated products







fillers





preservatives





## Context (2/2)

= AS

AS + co-formulants

Chemical reg.	REACH – CLP – POP		
PPP Reg.	1107/2009	1107/2009	1107/2009 (Art. 27)
Risk Management	National authorisations	European approval	European negative list (Annex III) Where <u>risk</u> identified
Risk Evaluation	Zonal assessment EU Requirements	European assessment EU requirements	Zonal and European assessment EU Requirements
Toxicology	Combined tox.	Single mol. tox.	May alter AS tox. or have specific tox. properties

Food Safet



## Setting Annex III

• Art. 27 mandates EC to set a list of unacceptable co-formulants as Annex III to Reg. (EC) 1107/2009. These unacceptable coformulants, or their residues cause a risk to human or animal health or to the environment, including ground waters.



#### WG on co-formulants

- MSs, EFSA and COM
- Discussions on criteria, risk assessment and procedure: working document
- Key decisions
  - Criteria in line with those provided for Active Substances
  - Keep Annex III entries proportionate and simple
  - Take advantage of existing data
  - Specific products/conditions of use dealt with at zonal level



#### Criteria

- A Tiered approach, considering the criticality of the concerns
  - Tier1: triggers based (<u>only</u>) on hazard classification ~ Annex III
    - Extrapolation from AS criteria (Annex II): CMR 1A/B, (ED)...
    - Extrapolation from REACH Annexes XIV/XVII: POP, PBT, SVHC...



#### Criteria

- Tier2: triggers based on hazard classification © <u>Risk assessment</u> © Annex III ?
  - CMR2, STOT RE1&2, Skin/Resp. Sens. 1, two criteria PBT...
- Tier3: triggers based on other informations
   Risk assessment
   Annex III ?
  - Risk concerns, new scientific information, unsubmitted preservatives (Reg. 528/2012)...



#### Procedure

coformulants of no concern

TIER 3

TIER 2

TIER 1

Zonal assessment taking into account the toxicity of relevant coformulants

Notification by MS noted in PAFF

Assessment by a RMS

Peer-review

Vote PAFF (PRAC)

Annex III, with w/o specific conditions



## Next steps

- Working document from the Working Group
  - Stakeholders to comment: 30/05/2016(in writing) SANTE-Advisory-Group@ec.europa.eu
- Impl. Act to set detailed rules for Annex III
- Setting Annex III (PRAC 3 months)
  - → MSs to identify candidates: 30/04/2016
    - Discussion: May/July PAFF
    - TBT during the summer break
      - ∇ote Q4 2016 at the earliest

### Thank you for your attention

Any questions?





